At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Giampaolo Bianchini, MD, of the San Raffaele Scientific Institute, Milan, Italy, explains the evidence requirements for the clinical development of prognostic and predictive genomic tests for individual risk stratification and adjuvant treatment selection in breast cancer patients.
Evaluating genomic tests for breast cancer management
13 Jan 2016
Oncology
Rate this content's potential impact on patient outcomes
Average rating / 5. Vote count:
No votes so far! Be the first to rate this content.
Thank you!
Please share some more information on the rating you have given